Definitive Healthcare Corp (DH)vsEli Lilly and Company (LLY)
DH
Definitive Healthcare Corp
$0.89
-1.11%
HEALTHCARE · Cap: $112.08M
LLY
Eli Lilly and Company
$1,170.45
+0.45%
HEALTHCARE · Cap: $994.92B
Smart Verdict
WallStSmart Research — data-driven comparison
Eli Lilly and Company generates 34135% more annual revenue ($79.67B vs $232.70M). LLY leads profitability with a 33.5% profit margin vs -72.3%. LLY earns a higher WallStSmart Score of 76/100 (B+).
DH
Hold37
out of 100
Grade: F
LLY
Strong Buy76
out of 100
Grade: B+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+76.2%
Fair Value
$7.09
Current Price
$0.89
$6.20 discount
Intrinsic value data unavailable for LLY.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Mega-cap, among the largest globally
Every $100 of equity generates 79 in profit
Keeps 34 of every $100 in revenue as profit
Strong operational efficiency at 54.2%
Revenue surging 47.7% year-over-year
Earnings expanding 26.2% YoY
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
Elevated debt levels
ROE of -116.5% — below average capital efficiency
Premium valuation, high expectations priced in
Elevated debt levels
Trading at 30.8x book value
Comparative Analysis Report
WallStSmart ResearchBull Case : DH
The strongest argument for DH centers on Price/Book.
Bull Case : LLY
The strongest argument for LLY centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 33.5% and operating margin at 54.2%. Revenue growth of 47.7% demonstrates continued momentum.
Bear Case : DH
The primary concerns for DH are EPS Growth, Market Cap, Debt/Equity.
Bear Case : LLY
The primary concerns for LLY are P/E Ratio, Debt/Equity, Price/Book. Debt-to-equity of 1.62 is elevated, increasing financial risk.
Key Dynamics to Monitor
DH profiles as a turnaround stock while LLY is a growth play — different risk/reward profiles.
DH carries more volatility with a beta of 1.40 — expect wider price swings.
LLY is growing revenue faster at 47.7% — sustainability is the question.
LLY generates stronger free cash flow (7.8B), providing more financial flexibility.
Bottom Line
LLY scores higher overall (76/100 vs 37/100), backed by strong 33.5% margins and 47.7% revenue growth. DH offers better value entry with a 76.2% margin of safety. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Definitive Healthcare Corp
HEALTHCARE · HEALTH INFORMATION SERVICES · USA
Definitive Healthcare Corp (DH) is a leading provider of comprehensive data and analytics solutions designed specifically for the healthcare industry, catering to a diverse clientele that includes pharmaceutical companies, payers, and healthcare providers. By harnessing extensive datasets and cutting-edge real-time analytics, Definitive Healthcare enhances operational efficiencies and delivers critical strategic insights, ultimately improving patient outcomes. With a strong commitment to innovation, the company is well-positioned to capitalize on the growing demand for sophisticated healthcare analytics, thereby establishing itself as a pivotal player in the transformation of healthcare delivery.
Visit Website →Eli Lilly and Company
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries.
Visit Website →Compare with Other HEALTH INFORMATION SERVICES Stocks
Want to dig deeper into these stocks?